Patents by Inventor Rosana GEROMETTA

Rosana GEROMETTA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glaucoma treatment
    Patent number: 11478536
    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
    Type: Grant
    Filed: May 8, 2020
    Date of Patent: October 25, 2022
    Assignees: The Research Foundation for The State University of New York, Icahn School of Medicine at Mount Sinai
    Inventors: Ioannis Danias, Oscar A. Candia, Rosana Gerometta
  • Glaucoma treatment
    Patent number: 10946076
    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: March 16, 2021
    Assignees: The Research Foundation for The State University of New York, Icahn School of Medicine at Mount Sinai
    Inventors: Ioannis Danias, Oscar A. Candia, Rosana Gerometta
  • GLAUCOMA TREATMENT
    Publication number: 20200268858
    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
    Type: Application
    Filed: May 8, 2020
    Publication date: August 27, 2020
    Applicants: The Research Foundation for The State University of New York, Icahn School of Medicine at Mount Sinai
    Inventors: Ioannis DANIAS, Oscar A. CANDIA, Rosana GEROMETTA
  • GLAUCOMA TREATMENT
    Publication number: 20150366953
    Abstract: Disclosed herein are methods of treatment for an intraocular pressure (IOP)-associated condition in a subject, that include administering to the subject an effective amount of a tissue plasminogen activator (tPA) therapeutic agent. In one embodiment, the IOP-associated condition is glaucoma. The administration of a tPA therapeutic agent can be an extended administration intended to cause a reduction in IOP in the subject for a period of at least one day to a year or more, relative to IOP levels in the subject prior to administration of the tPA therapeutic agent. The tPA therapeutic agent can be, for example, tPA, a tPA derivative, a small molecule direct or indirect tPA agonist, or a gene therapy vector.
    Type: Application
    Filed: February 12, 2014
    Publication date: December 24, 2015
    Applicants: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: John DANIAS, Oscar A. CANDIA, Rosana GEROMETTA